newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma reports first quarter 2026 results

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to